Free Trial
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel Free CNBX Stock Alerts
OTCMKTS:CNBX

CNBX Pharmaceuticals (CNBX) Stock Price, News & Analysis

CNBX Pharmaceuticals logo
$0.0001 0.00 (0.00%)
As of 02:02 PM Eastern
Compare

About CNBX Pharmaceuticals Stock (OTCMKTS:CNBX)

View Price History Chart DataSkip Price History Chart
Advanced
1 Day 5 Days 30 Days 90 Days 1 Year
Advanced

Key Stats

Today's Range
$0.0001
▼
$0.0002
50-Day Range
N/A
52-Week Range
$0.0001
▼
$0.0007
Volume
855,250 shs
Average Volume
25.04 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

CNBX Pharmaceuticals Corp. is a biotechnology company focused on researching cannabinoid-based approaches to cancer treatment and personalized medicine. The company’s work centers on evaluating how cannabinoids and cannabis-derived compounds may affect cancer cells.

CNBX has developed a proprietary cannabinoid research and screening platform designed to test cannabis formulations against patient-derived cancer cells. The platform is intended to support the identification of potentially effective cannabinoid combinations and help researchers study individualized treatment options.

The company’s activities have primarily involved research and development rather than the sale of an established commercial pharmaceutical product. Publicly available information about CNBX Pharmaceuticals’ current operations, geographic coverage and leadership is limited.

AI Generated. May Contain Errors.

Receive CNBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CNBX Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CNBX Stock News Headlines

CNBX Pharmaceuticals Inc. (OTCMKTS:CNBX) Short Interest Update
September 27, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31055672
Cannabics Pharmaceuticals Announces the Appointment of Dr. Yaakov Waksman as Head of Cannabidiol Research
July 29, 2026  |  nasdaq.comhttps://www.nasdaq.com/press-release/cannabics-pharmaceuticals-announces-the-appointment-of-dr.-yaakov-waksman-as-head-of
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.tc pixel
October 5 at 1:00 AM  |  Banyan Hill Publishing (Ad)
CNBX Pharmaceuticals Inc. (CNBX) stock forecast and price target
July 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/research/stock-forecast/CNBX/
CNBX Pharmaceuticals (OTC:CNBX) Stock Quotes, Forecast and News Summary
March 1, 2025  |  benzinga.comhttps://www.benzinga.com/quote/CNBX
CNBX Pharmaceuticals Stock (OTC:CNBX) Dividends: History, Yield and Dates
November 24, 2023  |  benzinga.comhttps://www.benzinga.com/quote/CNBX/dividend
CNBX Pharmaceuticals Inc CNBX
November 5, 2023  |  morningstar.comM
CNBX Historical Data
October 9, 2023  |  investing.comhttps://www.investing.com/equities/cannabics-pharmaceuticals-inc-historical-data
See More Headlines

CNBX Stock Analysis - Frequently Asked Questions

CNBX Pharmaceuticals' stock was trading at $0.0004 at the beginning of the year. Since then, CNBX shares have decreased by 75.0% and is now trading at $0.0001.

CNBX Pharmaceuticals's stock reverse split on the morning of Thursday, May 12th 2022.The 1-120 reverse split was announced on Thursday, May 12th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 12th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Shares of CNBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CNBX Pharmaceuticals investors own include Organigram Global (OGI), Green Thumb Industries (GTBIF), Canopy Growth (CGC), Curaleaf (CURLF), Kushco (KSHB) and Trulieve Cannabis (TCNNF).

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:CNBX
CIK
1343009
Web
cnbxpharma.com
Phone
(877) 424-2429
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (OTCMKTS:CNBX) was last updated on 10/5/2026 by MarketBeat.com Staff.
From Our Partners
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel